Simvastatin ameliorates testosterone-induced prostatic hyperplasia in rats via modulating IGF-1/PI3K/AKT/FOXO signaling
Date
2023-05
Journal Title
Journal ISSN
Volume Title
Type
Article
Publisher
Elsevier
Series Info
European Journal of Pharmacology;950, art. no. 175762.
Scientific Journal Rankings
Abstract
Benign prostatic hyperplasia (BPH) is characterized by non-malignant enlargement of prostate cells causing
many lower urinary tract symptoms. BPH pathogenesis includes androgens receptors signaling pathways,
oxidative stress, apoptosis, and possibly changes in IGF-1/PI3K/AKT/FOXO pathway. Altogether, modulating
IGF-1/PI3K/AKT/FOXO signaling along with regulating oxidative stress and apoptosis might preserve prostatic
cells from increased proliferation. Beyond statins’ common uses, they also have anti-inflammatory, antioxidant,
and anti-tumor effects. This study aims to determine simvastatin’s beneficial effect on testosterone-induced BPH.
Rats were randomly allocated into four groups, 9 rats each. The control group received olive oil subcutaneously
and distilled water orally for 30 consecutive days. The second group received simvastatin (20 mg/kg, p.o.)
dissolved in distilled water. The BPH-induced group received testosterone enanthate (3 mg/kg, s.c.) dissolved in
olive oil, and the BPH-induced treated group received both simvastatin and testosterone. Testosterone signifi-
cantly increased prostate index and severity of histopathological alterations in prostate tissues as well as 5-alpha
reductase enzyme level in contrast to simvastatin treatment that reversed the testosterone-induced alterations in
these parameters. Likewise, testosterone up-regulated IGF-1/PI3K/AKT signaling pathway and down-regulated
FOXO transcription factor. It also decreased apoptotic markers level in prostatic tissue BAX, caspase-3, and
caspase-9, while it elevated Bcl-2 level. In addition, it alleviated reduced GSH and GPX5 levels and SOD activity.
Simvastatin treatment significantly opposed testosterone’s effect on all aforementioned parameters. In conclu-
sion, this study demonstrates that simvastatin is a possible treatment for BPH which may be attributed to its
effect on IGF-1/PI3K/AKT/FOXO signaling pathway as well as anti-oxidant and apoptotic effects
Description
Keywords
Benign prostatic hyperplasia, Simvastatin, IGF-1, PI3K, AKT, FOXO